MedTrace Logo

Trifecta-Lung cfDNA-MMDx Study

NCT05837663 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2026-07-17

No results posted yet for this study

Summary

Demonstrate the relationship between dd-cfDNA levels and HLA antibodies in blood transplant recipient and Demonstrate the Molecular Microscope® (MMDx) Diagnostic System results in indication and protocol biopsies from lung transplants.

Conditions

  • Lung Transplantation

Sponsors & Collaborators

Principal Investigators

  • Philip F Halloran, MD PhD · Alberta Transplant Applied Genomics Centre, University of Alberta

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-01
Primary Completion
2027-11-30
Completion
2028-12-31

Countries

  • United States
  • Australia
  • Austria
  • Canada
  • Czechia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05837663 on ClinicalTrials.gov